| Interdepartmental Federal Cannabis Partners |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA, SAMHSA |
NCI, NIDA |
The Federal Cannabis Partners working group meets quarterly to discuss issues of interest related to cannabis and public health and to foster collaborations across HHS and other agencies. |
| Interdepartmental Health Equity Collaborative (IHEC) |
Committee, Work group, Advisory group, or Task Force |
ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA |
NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDDK, NIEHS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/ODP |
The Interdepartmental Health Equity Collaborative (IHEC), formerly known as Federal Interagency Health Equity Team (FIHET), is a trans-federal working group to address health equity in the US health systems. The mission of theis to convene federal leaders to end health disparities by building capacity for equitable policies and programs, cultivating strategic partnerships, and sharing relevant models for action. IHEC goals are to: 1) collaborate with diverse federal agencies to define linkages and implement coordinated approaches between their missions and health equity; 2) identify, develop, and integrate strategies with measurable outcomes to advance health equity in/through federal policies, programs, and activities; 3) leverage assets, influence, and experiences of federal agencies, partners, and communities to advance health equity; 4) generate, facilitate, and translate research, data, and emerging knowledge about health equity into practice and policy; and 5) educate and mentor leader and peers to develop equity champions within all federal agencies. https://minorityhealth.hhs.gov/npa/ |
| Interdepartmental Serious Mental Illness Coordinating Committee |
Committee, Work group, Advisory group, or Task Force |
SAMHSA, ACL, CMS |
NIMH |
In December 2016, the 21st Century Cures Act was signed into law (Public Law 114-255). Through this Act, the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) was established to address the needs of adults with serious mental illness (SMI) and children and youth with serious emotional disturbance (SED) and their families so that Americans with SMI and SED are able to improve their lives and receive the highest possible standard of care-care that is deeply informed by knowledge of science and medicine. The ISMICC includes representatives from eight federal departments that support programs that address the needs of people with SMI and SED and is informed and strengthened by the participation of non-federal members, including national experts on health care research, mental health providers, advocates, people with living with mental health conditions, and their families and caregivers. This cross-sector, public-private partnership provides a unique opportunity to share and generate solutions to the problems facing the mental health system. The ISMICC seeks to support a system where individuals with SMI or SED are able to engage effectively with a range of treatment and recovery support services that promote opportunities for people to live well in their communities. A central charge of this committee is to submit two reports to Congress, the first no later than one year after the enactment of the Act, and the second five years following enactment. The ISMICC has five priority areas and corresponding workgroups for these priority areas. Representatives from the National Institute of Mental Health (NIMH) sit on each of these workgroups. |
| International Cancer Control Partnership |
Other |
CDC |
NCI |
The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal for NCD control. ICCP partners will assist countries by: (1) Creating and maintaining a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Providing technical assistance to countries working to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Coordinating an online community of practice (through partnership with the University of New Mexico's Project ECHO) for dissemination and utilization of scientific knowledge for National Cancer Control Plan implementation. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. |
| International Cancer Screening Network (ICSN) |
Committee, Work group, Advisory group, or Task Force |
CDC |
NCI |
The International Cancer Screening Network (ICSN) is a voluntary consortium of screening practitioners who work in countries that are planning for or implemented population-based cancer screening programs with the mission of reducing the burden of cancer by promoting dialogue and collaborative cancer screening research, evaluation and dialogue regarding the effectiveness of context-specific evidence-based cancer screening programs, including promotion, recruitment and follow-up among other relevant topics. ICSN goals include:1. To provide global leadership in cancer screening research and evaluation by organizing scientific studies, biennial conferences, consultations, mentorship, training, and by publishing collaborative papers.2. To create a community of screening practitioners (researchers, evaluators, implementers and screening program staff) to exchange data, evidence, ideas and experiences that advance the field of cancer screening.3. To assist in the design of studies to evaluate the process and effectiveness of cancer screening programs; to evaluate and promote innovation in cancer screening through new technologies; to enhance the screening process for treatment of screen-detected lesions, among other topics.4. To be a source of education and dialogue about basic aspects of cancer screening as well as advanced and emerging concepts and technology.5. To include membership who conducts cancer screening research, develop infrastructure for cancer screening, and establish programs whose goal is to deliver the highest quality health care while producing the maximum benefit to the population and minimizing its harms. Other collaborative activities: health survey, meeting/workshop |
| International Lead Working Group |
Committee, Work group, Advisory group, or Task Force |
CDC, CDC, FDA |
FIC, NIEHS |
Working group to share lessons learned in the field of Pb from research to policy to regulation. |
| International Medical Countermeasure (MCM) Interagency Technical Working Groups |
Committee, Work group, Advisory group, or Task Force |
OGA, ASPR, CDC, FDA, OS |
NIAID |
The purpose of these Technical Working Groups is to establish a process to facilitate interagency technical discussions to: (1) advance a U.S. Government proposal for a global coordination hub which convenes and facilitates information sharing to help coordinate the implementation platforms and partners and improve equity and equitable access to MCMs (e.g., personal protective equipment, diagnostics, vaccines, therapeutics, etc.) during health emergencies; (2) ensure that any U.S. Government proposal will be credible internationally and can be effectively operationalized; and (3) inform the development and reexamination of U.S. Government policy positions relevant to longer-term solutions within and beyond the potential outcomes of the G20 process and other multilateral efforts including at the WHO and in the Working Group on Amendments to the International Health Regulations (2005) (WGIHR) IHR and Intergovernmental Negotiating Body (INB) negotiations. |
| International Neonatal Consortium |
Meeting/ Workshop |
FDA |
NICHD |
Launched on May 19, 2015, INC is C-Path’s ninth consortium – a global collaboration formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates. “By uniting stakeholders from research institutions, drug developers, regulatory agencies, patient advocacy and other organizations,” said Janet Woodcock, Director of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (FDA/CDER), “INC can develop practical tools that can be incorporated into clinical trials for neonates, which will then lead to more successful, efficient trials and provide this population with better treatments.” |
| International Working Group |
Committee, Work group, Advisory group, or Task Force |
CDC, FDA |
NIAID, NICHD, NIDDK |
This working group brings scientists from multiple Federal agencies together to discuss and present research regarding the various clinical research topics like human subjects protection and regulations governing clinical research. |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) |
Committee, Work group, Advisory group, or Task Force |
CDC, ASPR, FDA |
NIAID, OD/OM, OD/OM/ORS, OD/OSP |
The ISATTAC is a working group of subject matter experts from the Federal Government formed by the Centers for Disease Control and Prevention (CDC) Director to provide recommendations to the CDC's Division of Regulatory Science and Compliance in three technical areas: 1) review requests for exclusion of attenuated strains, 2) review requests to conduct restricted experiments, and 3) review select agents and toxins. The Committee conducts a biannual review, required by the Select Agent Rule, of the Select Agents and Toxins list for HHS. |